BRAF and melanoma: Synergistic activity was seen with TAK-733 in combination with the pan-RAF inhibitor TAK-632 in both BRAF-mutated melanoma cells and NRAS-mutated melanoma cells with acquired resistance to BRAF inhibitors [28].